Overview

Study in Subjects With Small Primary Choroidal Melanoma

Status:
Completed
Trial end date:
2021-01-26
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Aura Biosciences